3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
20
Carcinoma, Renal Cell
10
Neuroendocrine Tumors
7
Neoplasm Metastasis
7
Recurrence
4
Tuberous Sclerosis
3
Triple Negative Breast Neoplasms
3
Neoplasms
3
Kidney Neoplasms
3
Endometrial Neoplasms
3
von Hippel-Lindau Disease
2
Skin Neoplasms
2
Sarcoma
2
Meningioma
2
Glioma
2
Gastro-enteropancreatic neuroendocrine tumor
2
Diffuse Intrinsic Pontine Glioma
2
Carcinoma, Hepatocellular
2
Adenoma, Islet Cell
2
Waldenstrom Macroglobulinemia
1
Vascular Malformations
1
Unilateral Breast Neoplasms
1
Thyroid cancer, Hurthle cell
1
Thyroid Neoplasms
1
Thyroid Diseases
1
Thymus Neoplasms
1
Seizures
1
Sarcoma, Kaposi
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Interventions
pembrolizumab
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Cisplatin
4
Carboplatin
4
Biopsy
4
trastuzumab deruxtecan
3
Trastuzumab
3
Platinum
3
Goserelin
3
Docetaxel
3
sacituzumab govitecan
2
pertuzumab
2
entrectinib
2
darolutamide
2
Radiotherapy, Intensity-Modulated
2
Leuprolide
2
Ado-Trastuzumab Emtansine
2
1,2-diaminocyclohexaneplatinum II citrate
2
zanidatamab
1
trastuzumab biosimilar HLX02
1
spartalizumab
1
selinexor
1
pyrotinib
1
luprolide acetate gel depot
1
lenvatinib
1
larotrectinib
1
enfortumab vedotin
1
dehydroftorafur
1
ceralasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
Everolimus
×
1 year
×
Clear all
No trials found.